The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences

References

• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low‐dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984; 144: 1947–53
   PubMed Web of Science ®Google Scholar
• The Consensus Trial Group. Effect of Enalapril on mortality in severe congestive heart failure:results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 625–91
   Google Scholar
• Pfeffer M. A., Braunwald E., Morge L. A., Basta L., Brown E. J Jr., Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of Enalapril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77
   PubMed Web of Science ®Google Scholar
• Lonn E. M., Yusuf S., Jha P., Montague T. M., Teo K. K., Benedict C. R., Pitt B. Emerging role of angiotensin – converting enzyme inhibitor in cardiac and vascular protection. Circulation 1994; 90: 2056–69
   PubMed Web of Science ®Google Scholar
• Steinberg D., Parsathanathy S., Carew T. E., Khoo J., Witzum J. Beyond Cholesterol. Modifications of low‐density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24
   PubMed Web of Science ®Google Scholar
• Berry E. M. The effects of nutrients on lipoprotein susceptibility to oxidation. Curr Opin Lipidol 1992; 3: 5–11
   Google Scholar
• Gey K. F., Puska P., Jordan P., Moser U. K. Inverse correlation between plasma, Vitamin E and mortality from ischemic heart disease in cross‐cultural epidemiology. Am J Clin Nutr 1991; 53((Suppl1))5326–34
   Google Scholar
• Stampfer M. J., Hennekens C. H., Manson J. A. A prospective study of Vitamin E consumption and risk for coronary disease in women. N Engl J Med 1993; 328: 1444–49
   PubMed Web of Science ®Google Scholar
• Rimm E. B., Stampfer M. J., Ascherio A. Vitamin E consumption and risk of coronary heart disease among men. N Engl J Med 1993; 32: 1450–56
   Google Scholar
• Jha P., Flather M., Lonn E., Farkouh M., Yusuf S. The Antioxidant Vitamins and Cardiovascular Disease. A Critical Review of Epidemiologic Clinical Trial Data. Ann Int Med 1995; 123: 860–72
   PubMed Web of Science ®Google Scholar
• The HOPE (Heart Outcomes Prevention Evaluation) Study. The design of a large, simple randomized trial of an angiotensin‐converting enzyme inhibitor (Ramipril) and Vitamin E in patients at high risk of cardiovascular events. The HOPE Study Investigators. Can J Cardiol 1995; 12: 127–37
   Google Scholar
• Lonn E. M., Yusuf S., Doris C. I., Sabrine M. J., Dzavik V., Hutchison K., Riley W. A., Tucher J., Pogue J., Taylor W., for the SECURE Investigators. Am J Cardiol 1996; 78: 914–19
   PubMedGoogle Scholar
• Gerstein H. C., Bosch J., Pogue J., Wayne taylor D., Zinman B., Yusuf S. The HOPE Study Investigators. Rationale and Design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and Vitamin E in high‐risk patients with diabetes. The MICRO‐HOPE study. Diabetes Care 1996; 19: 1225–28
   PubMedGoogle Scholar
• Effects of an angiotensin‐converting‐enzyme inhibitor. Ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53
   PubMedGoogle Scholar
• Dagenais G., Yusuf S., Bourassa M. G., Yi Q., Bosch J., Lonn E. M., Kouz S., Grover J., on behalf of the HOPE investigators. Effects of Ramipril on coronary events in high‐risk persons. Results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104: 522–26
   PubMed Web of Science ®Google Scholar
• Sleight P., Yusuf S., Pogue J., Tsuyuki R., Diaz R., Probstfield J., for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Blood‐pressure reduction and cardiovascular risk in HOPE Study. (Letter) Lancet 2001; 358: 2130–31
   PubMed Web of Science ®Google Scholar
• Vitamin E. Supplementation and Cardiovascular Events in High‐Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154–160
   PubMedGoogle Scholar
• Lonn E. M., Yusuf S., Dzavik V., Doris I., Yi Q., Smith S., Moore‐cox A., Bosch J., Riley W. A., Teo K. K., for the SECURE Investigators. Effects of Ramipril and Vitamin E on Atherosclerosis. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919–25
   PubMed Web of Science ®Google Scholar
• Lonn E., Roccaforte R., Yi Q., Dagenais G., Sleight P., Bosch J., Suhan P., Micks M., Probstfield J., Bernstein V., Yusuf S., on behalf of the HOPE Investigators. Effect of long‐term therapy with Ramipril in high‐risk women. J Am Coll Cardiol 2002; 4: 693–702
   Google Scholar
• Lorell B. H. ACE inhibitors after myocardial infarction. (Letter to the Editor) N Engl J Med 1993; 328: 966–67
   PubMedGoogle Scholar
• Klein W. Gender differences in clinical trials in coronary heart disease:response in drug therapy. Eur Heart J 1996; 17: 1786–90
   PubMedGoogle Scholar
• Schumkert H., Danser A. H. J., Hense H. W. Effects of estrogen replacement therapy on the renin‐angiotensin system in postmenopausal women. Circulation 1947; 95: 39–45
   Google Scholar
• Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., Davis R., Ostergren J., Probstfield J., on behalf of the HOPE Investigators. Use of Ramipril in preventing stroke:double blind randomized trial. BMJ 2002; 324: 1–5
   PubMed Web of Science ®Google Scholar
• Schrader J., Lüders S. Preventing stroke (Editorial). BMJ 2002; 324: 699–703
   PubMedGoogle Scholar
• Stys T., Lawson W. E., Smaldone G. C., Stys A. Does aspirin attenuate the beneficial effects of angiotensin‐converting enzyme inhibition in heart failure?. Arch Intern Med 2000; 160: 1409–13
   PubMedGoogle Scholar
• Teo K. K., Yusuf S., Pfeffer M., Kober L., Hall A., Pogue J., Latini R., Collins R., for the ACE Inhibitors Collaborative Group. Lancet 2002; 360: 1037–43
   PubMed Web of Science ®Google Scholar
• Ostergren J., Sleight P., Dagenais G., Danisa K., Bosch J., Yi Q., Yusuf S., for the HOPE Study Investigators. Impact of Ramipril in patients with evidence of clinical or sub‐clinical peripheral arterial disease. Europ Heart J 2004; 25: 17–24
   PubMed Web of Science ®Google Scholar
• Svensson P., De faire U., Sleight P., Yusuf S., Stergren J. Comparative effects of Ramipril on ambulatory and office blood pressures. A HOPE Sub‐study. Hypertension 2001; 38: e28–e32
   PubMed Web of Science ®Google Scholar
• Eikelboom J. W., Hirsh J., Weitz J. I., Johnston M., Yi Q., Yusuf S. Aspirin‐resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–55
   PubMed Web of Science ®Google Scholar
• Kammel W. B., Gordon T., Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med 1969; 71: 89–101
   PubMedGoogle Scholar
• Schmeder R. E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996; 275: 1507–13
   PubMedGoogle Scholar
• Roman M. J., Alderman M. H., Pickering T. G. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass and vascular hypertrophy. Am J Hypertens 1998; 11: 387–96
   PubMed Web of Science ®Google Scholar
• Lonn E., Mathew J., Pogue J., Johnstone D., Danisa K., Bosch J., Baird M., Dagenais G., Sleight P., Yusuf S., on behalf of the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high‐risk patients. Eur J Cardiovasc Prevention Rehab 2003; 10: 420–28
   PubMedGoogle Scholar
• Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., Bosch J., Sussex B., Probstfield J., Yusuf S., for the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy of the angiotensin‐converting enzyme inhibitor Ramipril. Circulation 2001; 104: 1616–21
   Google Scholar
• Lonn E., Shaikholeslami R., Yi Q., Bosch J., Sullivan B., Tanser P., Magi A., Yusuf S. Effects of Ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 2200–6
   PubMed Web of Science ®Google Scholar
• Teo K. K., Mitchell B., Pogue J., Bosch J., Dagenais G., Yusuf S., on behalf of the HOPE Investigators. Effect of Ramipril in reducing sudden deaths and non‐fatal cardiac arrests in high‐risk individuals without heart failure or left ventricular dysfunction. Circulation 2004; 110: 1413–17
   PubMed Web of Science ®Google Scholar
• Arnold J. M. O., Yusuf S., Young J., Mathew J., Johnstone D., Avegam A., Lonn E., Pogue J., Bosch J., on behalf of the HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 1284–90
   PubMed Web of Science ®Google Scholar
• Parfrey P. S., Foley R. N. The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 1999; 10: 1053–58
   Google Scholar
• Mann J. F. E., Gerstein H. C., Pogue J., Lonn E., Yusuf S. Cardiovascular risk in patients with early renal insufficiency. Implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2002; 2: 157–62
   PubMedGoogle Scholar
• Boaz M., Smetana S., Weinstein T. Secondary prevention with antioxidants of cardiovascular disease in end‐stage renal disease (SPACE):randomized placebo‐controlled trial. Lancet 2000; 356: 1213–18
   PubMed Web of Science ®Google Scholar
• Mann J. F. E., Lonn E. M., Yi Q., Gerstein H. C., Hoogwerf B. J., Pogue J., Bosch J., Dagenais G. R., Yusuf S., on behalf of the HOPE investigators. Effects of Vitamin E in cardiovascular outcomes in people with mild‐to‐moderate renal insufficiency:results of the HOPE study. Kidney Int 2004; 65: 1375–80
   PubMed Web of Science ®Google Scholar
• Mann J. F. E., Gerstein H. C., Pogue J., Bosch J., Yusuf S., for the HOPE investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of Ramipril:the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36
   PubMed Web of Science ®Google Scholar
• Mann J. F. E., Gerstein H. C., Yi Q., Franks J., Lonn E. M., Hoogwerf B. J., Rashkow A., Yusuf S., on behalf of the HOPE investigators. Progression of renal insufficiency in type 2 diabetes with or without microalbuminuria:results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003; 42: 936–42
   PubMed Web of Science ®Google Scholar
• Gerstein H. C., Mann J. F. E., Pogue J., Dineen S. F., Hallé J‐P., Hoogwerf B., Joyce C., Rashkow A., Young J., Zinman B., Yusuf S., on behalf of the HOPE study investigators. Prevalence and determinants of microalbuminuria in high‐risk diabetic and non‐diabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 2000; 23((Suppl2))B35–B39
   Google Scholar
• Gerstein H. C., Mann J. F. E., Yi Q., Zinman B., Dineen S., Hoogwerf B., Hallé J‐P., Young J., Rashkow K., Joyce C., Nawaz S., Yusuf S., for the HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non‐diabetic individuals. JAMA 2001; 286: 421–26
   PubMed Web of Science ®Google Scholar
• Meltzer S., Leiter L., Daneman D. 1998 Clinical Practice Guidelines for the Management of Diabetes in Canada. Can Med Assoc J 1998; 159((Suppl 8))S1–S29
   Web of Science ®Google Scholar
• Mann J. F. E., Gerstein H. C., Yi Q., Lonn E. M., Hoogwerf B. J., Rashkow A., Yusuf S., on behalf of the HOPE investigators. Development of renal disease in people at high cardiovascular risk:results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641–47
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO‐HOPE substudy. Lancet 2000; 355: 253–59
   PubMed Web of Science ®Google Scholar
• Lonn E., Yusuf S., Hoogwerf B., Pogue J., Yi Q., Zinman B., Bosch J., Dagenais G., Mann J. F. E., Gerstein H. C., on behalf of the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Effects of Vitamin E on cardiovascular and microvascular outcomes in high‐risk patients with diabetes. Diabetes Care 2002; 25: 1919–27
   PubMed Web of Science ®Google Scholar
• Levy A. P., Gerstein H. C., Miller‐lotan R., Ratner R., Mcqueen M., Lonn E., Pogue J. The effect of Vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004; 27: 2767
   PubMed Web of Science ®Google Scholar
• Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolfenbuttel B. H. R., Zuisman B., for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–85
   PubMed Web of Science ®Google Scholar
• Dagenais G. R., Auger P., Bogaty P., Gerstein H., Lonn E., Yi Q., Yusuf S., On behalf of the HOPE Study Investigators. Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. Can J Cardiol 2003; 19: 1387–91
   PubMed Web of Science ®Google Scholar
• Fabricant C. G., Fabricant J., Litrenta M. M. Virus‐reduced atherosclerosis. J Exp Med 1978; 148: 335–40
   PubMed Web of Science ®Google Scholar
• Smieja M., Gnarpe J., Lonn E., Gnarpe H., Olsson G., Yi Q., Dzavik V., Mcqueen M., Yusuf S., for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Circulation 2003; 107: 251–57
   PubMed Web of Science ®Google Scholar
• Veres A., Füst G., Smieja M., Mcqueen M., Horvath A., Yi Q., Biró A., Pogue J., Romics L., Karádi I., Singh M., Gnarpe J., Proháska Z., Yusuf S., for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Relationship of anti‐60kDa Heat Shock Protein and Anti‐Cholesterol Antibodies to Cardiovascular Events. Circulation 2002; 106: 2775–2780
   PubMedGoogle Scholar
• Schmidt M. I., Duncan B. B., Sharrett A. R. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in community study):a cohort study. Lancet 1999; 353: 1649–52
   PubMed Web of Science ®Google Scholar
• Meigs J. B., Hu F. B., Rifai N., Manson J. E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978–86
   PubMed Web of Science ®Google Scholar
• Lamy A., Yusuf S., Pogue J., Gabni A., on behalf of the HOPE Investigators. Cost implications of the use of Ramipril in high‐risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 960–65
   PubMed Web of Science ®Google Scholar
• Carroll C. A., Coen M. M., Piepbo R. W. Economic impact of Ramipril on hospitalization of high‐risk cardiovascular patients. Ann Pharmacotherapy 2003; 37: 327–31
   PubMedGoogle Scholar
• Malik I. S., Bhatia V. K., Kooner J. S. Cost effectiveness of Ramipril treatment for cardiovascular risk reduction. Heart 2001; 85: 539–43
   PubMedGoogle Scholar
• Björholt F. L., Anderson F. L., Kahan T., östergren J. The cost‐effectiveness of Ramipril in the treatment of patients at high risk of cardiovascular events:a Swedish sub‐study to the HOPE study. J Int Med 2002; 251: 508–17
   PubMed Web of Science ®Google Scholar
• Dzau V. J., Bernstein K., Celermajer D. Pathophysiologic and therapeutic importance of tissue ACE:a consensus report. Cardiovasc Drugs Ther 2002; 16: 149–60
   PubMed Web of Science ®Google Scholar
• Lonn E., Gerstein H. C., Smieja M., Mann J. F. E., Yusuf S. Mechanisms of cardiovascular risk reduction with Ramipril:insights from HOPE and HOPE substudies. Eur Heart J Supplements 2003; 5((Suppl A))A43–A48
   Google Scholar
• Smieja M., Yusuf S., Lonn E. Inflammatory markers and subsequent cardiovascular events in the HOPE trial. Circulation 2001; 17((Suppl II))II–791, Abstract 11363
   Google Scholar